APR-246 was also noted to demonstrate enhanced synergy with inhibitors of other cancer signalling, including proteosome inhibitor carfilzomib [173], BRAF inhibitor vemurafenib [174], Poly (ADP-ribose) polymerase (PARP) inhibitor Olaparib [175], etc. Other mutant p53 reactivating strategies also show promise for combination therapy. Here, TP53 is linked to cancer.